Is GMED overvalued right now?
Based on our 2026 models, Globus Medical, Inc. (GMED) appears overvalued at $86.91 with roughly 52.5% downside versus fair value. Confirm with valuation ratios and financials before acting.
Globus Medical, Inc. (GMED) is currently Overvalued by 52.45%
Instant valuation answer
Globus Medical, Inc. (GMED) appears overvalued by approximately 52.45% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Downside (live) 52.45% (from live valuation API)
- Confidence (live) 8.5/10 (High conviction overvalued)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$86.91
Explore Our Valuation Calculators
Why is Globus Medical, Inc. overvalued or undervalued?
For Globus Medical, Inc., intrinsic value ties fair value to sustainable cash generation; with the stock above that level, the snapshot reads as a premium versus fundamentals rather than a pure sentiment call.
Historical valuation for GMED shows cycles where multiples expanded and compressed; today’s positioning rhymes more with growth optimism than the mid-range of its recent history.
Market expectations boil down to growth, risk, and return on capital—current levels bake in strong execution, so disappointments hit harder. Cross-check with live ratios when your API is connected.
Key metrics
- P/E ratio
- 13.1x
- Revenue growth (TTM y/y)
- 10%
- Profit margin
- 36.4%
- Fair value (model)
- Unlock
Frequently asked questions — GMED
What is Globus Medical, Inc.'s intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether GMED trades above or below fair value. At $86.91, Globus Medical, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Globus Medical, Inc.'s intrinsic value calculated?
Tickerplace calculates GMED's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is GMED undervalued right now?
A stock is undervalued when price sits below a supportable fair value range. Check whether GMED's gap aligns with fundamentals using the ratios and financial links on this page.